Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2012-05-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to describe the safety and tolerability of up to 5 years (ie, 3
years under the 20040138 Amgen study and 2 years on this study) denosumab administration as
measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who
previously received denosumab for non-metastatic prostate cancer.